ABCELLERA BIOLOGICS (ABCL) is drawing unusual attention today. Our newswire has captured 5 stories on ABCL across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
ABCL stock is moving lower today after opening with a small gap up, as intraday action shows a sharp decline from the morning high to a session low near $5.82. The stock is down nearly 8% from its opening price, trading at $5.87 in afternoon trading. The move follows a recent upgrade from Cantor Fitzgerald to Overweight at $11 and a separate price target of $11 from Benchmark, but the stock remains below both levels.
Cantor Fitzgerald reissued an Overweight rating on AbCellera stock with a $11 price target, reaffirming its positive outlook despite the stock's recent pullback. This follows a preclinical research collaboration and licensing agreement between AbCellera and Jazz Pharmaceuticals, which aims to develop next-generation T-cell engaging multispecific antibodies. The partnership was announced earlier this year and is seen as a strategic move to expand AbCellera’s oncology pipeline. Additionally, AbCellera reported Q1 results that beat estimates, with revenue of $8.315 million and an EPS of -$0.14, which was better than expected. Despite these developments, the stock has declined over 19% in the past eight sessions.
The stock opened at $6.50, a modest 0.5% gap up from the previous close, but quickly reversed direction. Volume so far is 4.4 million shares, or 0.7 times the 3-month average, indicating moderate participation. The stock has traded between $2.75 and $8.44 over the past 52 weeks, and is currently near the lower end of that range. AbCellera remains unprofitable with a TTM net margin of -181.7% and a TTM revenue increase of 242.7%. A recent insider transaction shows John S. Montalbano, a director, bought shares on May 14, 2026, and another purchase was reported on May 18, 2026, totaling $95,000 in buys with no sells.
Investors should monitor the stock’s performance ahead of any further updates from the Jazz Pharmaceuticals collaboration or additional analyst commentary. No upcoming earnings date is provided, but coverage breadth and analyst ratings will remain key indicators.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
AbCellera Biologics ( ($ABCL) ) has provided an update. On July 29, 2026, AbCellera Biologics announced a collaboration with Vertex Pharmaceuticals to research, dev...
Filed: 2026-07-29 AccNo: 0001703057-26-000039 Size: 746 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
AbCellera (ABCL) stock gains as the company partners with Vertex Pharmaceuticals (VRTX) to discover T-cell engagers in exchange for $28M upfront. Read more here.
AbCellera lands a major collaboration with Vertex Pharmaceuticals, spotlighting its proprietary T-Cell Engager (TCE) platform and unlocking up to $28 million in upfront payments with additional potential milestone and royalty rewards. Here’s what this new partnership could mean for both companies and the field of autoimmune treatment.
ABCELLERA BIOLOGICS (ABCL) is drawing unusual attention today. Our newswire has captured 5 stories on ABCL across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100). The most recent driver: "AbCellera and Vertex launch autoimmune T-cell engager partnership" (TipRanks).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ABCL coverage reads 62/100 over 5 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on ABCL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ABCL move explainers: 2026-07-20